Pyxis Oncology, Inc. SEC filings PYXS
Pyxis Oncology, Inc. has 356 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 27, 2026 | — |
| EFFECT | Filing | Dec 9, 2025 | — |
| CORRESP | Letter to the SEC | Dec 8, 2025 | — |
| EFFECT | Filing | Apr 3, 2024 | — |
| CORRESP | Letter to the SEC | Apr 1, 2024 | — |
| UPLOAD | Letter from the SEC | Mar 29, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 6, 2023 | — |
| CORRESP | Letter to the SEC | Aug 28, 2023 | — |
| EFFECT | Filing | Aug 24, 2023 | — |
| UPLOAD | Letter from the SEC | Aug 16, 2023 | — |
| 425 | Filing | Aug 11, 2023 | — |
| 425 | Filing | Aug 11, 2023 | — |
| EFFECT | Filing | Jun 30, 2023 | — |
| 425 | Filing | Jun 30, 2023 | — |
| CORRESP | Letter to the SEC | Jun 29, 2023 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2023 | — |
| 425 | Filing | May 30, 2023 | — |
| 425 | Filing | May 25, 2023 | — |
| 425 | Filing | May 24, 2023 | — |
| 425 | Filing | May 24, 2023 | — |
| 425 | Filing | May 24, 2023 | — |
| 425 | Filing | May 24, 2023 | — |
| EFFECT | Filing | Nov 14, 2022 | — |
| CORRESP | Letter to the SEC | Nov 10, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 3, 2022 | — |
| EFFECT | Filing | Oct 7, 2021 | — |
| SEC STAFF LETTER | Filing | Oct 7, 2021 | — |
| CERT | Filing | Oct 6, 2021 | — |
| 8-A12B | Filing | Oct 5, 2021 | — |
| CORRESP | Letter to the SEC | Oct 5, 2021 | — |
| CORRESP | Letter to the SEC | Oct 5, 2021 | — |
| CORRESP | Letter to the SEC | Sep 28, 2021 | — |
| SEC STAFF LETTER | Filing | Sep 17, 2021 | — |
| DRS/A | Filing | Sep 10, 2021 | — |
| DRSLTR | Filing | Sep 9, 2021 | — |
| UPLOAD | Letter from the SEC | Aug 18, 2021 | — |
| DRSLTR | Filing | Aug 4, 2021 | — |
| DRS/A | Filing | Aug 4, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 16, 2021 | — |
| DRS | Filing | Jun 21, 2021 | — |
| D | Filing | Mar 22, 2021 | — |
| D | Filing | Jul 12, 2019 | — |
Showing 42 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PYXS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782223
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.